To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone marrow allograft recipients who have at least Grade II GvHD.
This is a Phase I, open-label dose escalation trial of MEDI-507 in pediatric SCT and BMT recipients with at least Grade II acute GvHD. All patients will receive steroid therapy and MEDI-507 for treatment of GvHD
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Children's Hospital
Birmingham, Alabama, United States
Children's Hospital of Orange County
Orange, California, United States
Children's Memorial Hospital
Chicago, Illinois, United States
Univ. of Michigan Medical Center
Ann Arbor, Michigan, United States
Safety assessment of escalating dose levels of MEDI-507 in pediatric stell scell (SCT) and bone marrow (BMT) allograft recipients who have at least Grade II Graft-versus-Host Disease (GvHD).
Time frame: Through Study Day 44
Evaluate the serum concentrations and pharmacokinetics (PK) of MEDI 507 and pharmacodynamic effects of MEDI-507 on the absolute lymphocyte count and dynamics of lymphocyte phenotypes.
Time frame: Through Study Day 364
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hackensack U. Medical Center
Hackensack, New Jersey, United States
The Children's Hosp. of Phila., Abramson Ped. Research Center
Philadelphia, Pennsylvania, United States